Everything below concerns anti-doping category. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-11. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilised material; shade varies slightly between lots |
| Solubility in water | Freely soluble | Dissolves in water, saline, and aqueous buffers |
| Solubility in nonpolar solvents | Poorly soluble | Not compatible with oils or hydrocarbon solvents |
| Typical storage temperature | About −20 °C | Lyophilised, dry, dark storage slows hydrolysis |
| Common purity method | Reversed-phase HPLC | Area percentage, usually paired with mass spectrometry |
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
Trichilia catigua is a flowering plant species in the genus Trichilia. The species is used in folk medicine and shamanism in the aphrodisiac and stimulant catuaba. Cinchonain-Ib is a flavonolignan found in the bark of T. catigua. Catuaba from Trichilia catigua was found to increase the release of Serotonin as well as Dopamine in rats. Additionally, Trichilia catigua was shown to have neuroprotective effects in rats.
=== Oakley et al. (2013) === In 2013 combined study of morphology, including fossils, and molecular data, including expressed sequence tag, mitochondrial genome, nuclear genome, and ribosomal DNA data, Oakley et al. obtained support for three pancrustacean clades: Oligostraca (Ostracoda, Mystacocarida, Branchiura, Pentastomida), Multicrustacea (Copepoda, Thecostraca, Malacostraca) and a clade they refer to as Allotriocarida (Branchiopoda, Cephalocarida, Remipedia, Hexapoda), as well as for monophyly of Ostracoda. Within Multicrustacea they obtained support for a clade they suggest the name Hexanauplia: Thecostraca + Copepoda. Relations within Allotriocarida remain uncertain: sister taxon to Hexapoda is either Remipedia, or the clade Branchiopoda + Cephalocarida, however, authors are inclined to the first version (see "Conclusion", 4), which is also consistent with von Reumont et al. (2012) results. New proposed by Oakley et al. clades are:
=== Use of confidentiality agreements === A New York Times investigation revealed that Johnson used confidentiality agreements to control his public image and that of his companies. Some of his workers have joined forces to challenge those agreements. Johnson defended his use of confidentiality agreements on social media, saying "I post nudes on social media. I track my nighttime erections. My team openly discusses my semen health... Rather than letting people walk in blind, we disclose this upfront, in writing, so there are no surprises."
25298Cf + 115B → 263103Lr* → 258103Lr + 5 10n The first work at Dubna on element 103 came in 1965, when they reported to have made 256Lr in 1965 by bombarding 243Am with 18O, identifying it indirectly from its granddaughter fermium-252. The half-life they reported was somewhat too high, possibly due to background events. Later 1967 work on the same reaction identified two decay energies in the ranges 8.35–8.50 MeV and 8.50–8.60 MeV: these were assigned to 256Lr and 257Lr. Despite repeat attempts, they were unable to confirm assignment of an alpha emitter with a half-life of 8 seconds to 257Lr. The Russians proposed the name "rutherfordium" for the new element in 1967; this name was later proposed by Berkeley for element 104.
{\displaystyle {\begin{aligned}{\frac {D\omega _{i}}{Dt}}&={\frac {\partial \omega _{i}}{\partial t}}+v_{j}{\frac {\partial \omega _{i}}{\partial x_{j}}}\\&=\omega _{j}{\frac {\partial v_{i}}{\partial x_{j}}}-\omega _{i}{\frac {\partial v_{j}}{\partial x_{j}}}+e_{ijk}{\frac {1}{\rho ^{2}}}{\frac {\partial \rho }{\partial x_{j}}}{\frac {\partial p}{\partial x_{k}}}+e_{ijk}{\frac {\partial }{\partial x_{j}}}\left({\frac {1}{\rho }}{\frac {\partial \tau _{km}}{\partial x_{m}}}\right)+e_{ijk}{\frac {\partial B_{k}}{\partial x_{j}}}\end{aligned}}}
Sources: en.wikipedia.org
== Second round proper == The draw for the second round was made on BBC Two on 7 November 2022 by Jermaine Beckford and Mickey Thomas at the Racecourse Ground in Wrexham, and consisted of the 40 winners from the previous round. The round contained one team from the seventh tier, Alvechurch, who defeated EFL League One club Cheltenham Town in the first round.
== Chemistry == The oxidation reaction that converts adrenaline into adrenochrome occurs both in vivo and in vitro. Silver oxide (Ag2O) was among the first reagents employed for this, but a variety of other oxidizing agents have been used successfully. In solution, adrenochrome is pink and further oxidation of the compound causes it to polymerize into brown or black melanin compounds.
The linker histone, or H1 protein, is also involved maintaining nucleosome structure. The H1 protein has the special role of ensuring that DNA stays tightly wound. Modifications to histone proteins and their DNA are classified as quaternary structure. Condensed chromatin, heterochromatin, prevents transcription of genes. In other words, transcription factors cannot access wound DNA- This is in contrast to euchromatin, which is decondensed, and therefore, readily accessible to the transcriptional machinery. DNA methylation to nucleotides influences chromatin quaternary structure. Highly methylated DNA nucleotides are more likely found within heterochromatin whereas unmethylated DNA nucleotides are common in euchromatin. Furthermore, post-translational modifications can be made to the core histone tail domains, which lead to changes in DNA quaternary structure and therefore gene expression. Enzymes, known as epigenetic writers and epigenetic erasers, catalyze either the addition or removal of several modifications to the histone tail domains. For instance, an enzyme writer can methylate Lysine-9 of the H3 core protein, which is found in the H3 histone tail domain. This can lead to gene repression as the chromatin gets remodeled and resembles heterochromatin. However, dozens of modifications can be made to histone tail domains. Therefore, it is the sum of all those modifications that determine whether chromatin will resemble heterochromatin or euchromatin.
In the Philippines, 7-Eleven was run by the Philippine Seven Corporation (PSC). Its first store, located at the corner of EDSA and Kamias Road in Quezon City, opened on February 29, 1984. On July 28, 1988, PSC transferred the Philippine area license to operate 7-Eleven stores to its affiliate, Phil-Seven Properties Corporation ("PSPC"), together with some of its store properties. In exchange thereof, PSC received 47% of PSPC stock as payment. On May 2, 1996, the stockholders of both PSC and PSPC approved the merger of the two companies to advance PSC group's expansion. On October 30, 1996, Securities and Exchange Commission approved the merger and PSPC was then absorbed by PSC as the surviving entity. In 2000, President Chain Store Corporation (PCSC) of Taiwan, also a licensee of 7-Eleven, purchased the majority shares of PSC and thus formed a strategic alliance for the convenience store industry within the area. In February 2009, 7-Eleven signed a non-exclusive contract with Chevron Philippines to open its stores in selected Caltex gas stations nationwide. In 2012, they opened their first store outside of Luzon in Cebu City, which soon expanded to the other parts of Cebu as well as its neighboring provinces. It was followed with the branch openings in Bacolod in 2013, Iloilo City in 2014, Davao City and Cagayan de Oro in 2015. The number of stores eventually spread from these major cities to smaller towns and provinces near them.
Sources: en.wikipedia.org
Lyophilised peptide powders are generally kept frozen or refrigerated, dry, and protected from light. Sealed vials limit moisture uptake and slow hydrolysis. Such guidance comes from general peptide chemistry rather than from stability studies specific to every product.
Reversed-phase HPLC is the standard approach, with purity expressed as a percentage of total peak area. Mass spectrometry confirms the expected molecular mass and can reveal adducts or truncated sequences. Neither method on its own establishes biological activity.
Small mass differences often reflect different counterions, such as acetate versus trifluoroacetate, or bound water rather than a different amino acid sequence. Mass spectrometry can distinguish these forms when the ionisation conditions are known. Exact sequence confirmation requires peptide mapping or tandem mass spectrometry.
Bacteriostatic water or sterile saline is commonly used to dissolve the powder. The choice of solvent affects stability and preservation. Aqueous solutions are kept refrigerated and are not intended for long-term storage.